Sulesomab

Summary

Sulesomab (CHEMBL2108809) is an approved antibody (ATC V09HA04); indicated across 2 conditions including osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: V09HA04
• Indications: 2 conditions
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108809
Name	Sulesomab
Type	Antibody
Max phase	4
ATC	V09HA04

Also known as: IMMU-MN-3, IMMU-MN3, Leukoscan, Sulesomab, Technetium (99mtc) sulesomab, Technetium tc 99m sulesomab, SULESOMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteomyelitis	4	MONDO:0005246	EFO:0003102

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01322256	Not specified	TERMINATED	PET/CT Scanning for the Follow-up of Antibiotic Treatment of Infectious Osteoarthritis in the Diabetic Foot

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).